Diagnostic Products Corp.
This article was originally published in The Gray Sheet
Executive SummaryPresident Sidnew Aroesty resigns "for personal reasons," effective Sept. 30, the company says. Aroesty, a 17-year veteran of DPC, will continue to serve on the board and will act as a consultant to the firm. He will be succeeded by Michael Ziering, who most recently served as the firm's vice president of administration. In addition, Aroesty has resigned as president of Cirrus Diagnostics, DPC's wholly owned subsidiary. Douglas Olsen, VP and executive VP for Cirrus, will take over the position
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.